The prospects of retinoids in the treatment of prostrate cancer

Lisette Hammond, Geoffrey Brown, Richard Keedwell, Jennifer Durham, RAS Chandraratna

Research output: Contribution to journalArticle

31 Citations (Scopus)


Prostate cancer is the most prevalent cancer amongst males and accounts for 13% of cancer deaths in this population in the US. Aggressive, androgen-independent, metastatic prostate cancer is incurable, and the search for new therapies has been directed towards identifying agents that block proliferation and induce differentiation and/or apoptosis of prostate cancer cells. Retinoid receptor agonists, such as all-trans retinoic acid, can induce apoptosis of prostate cancer cells, but clinical studies have demonstrated only mild to moderate efficacy. Retinoic acid receptor antagonists are a new class of retinoids, and pre-clinical studies have shown that they potently inhibit the growth of prostate cancer cells and induce apoptosis. Here, we review whether retinoids have a role in the fight against prostate cancer. [(C) 2002 Lippincott Williams Wilkins.].
Original languageEnglish
Pages (from-to)781-790
Number of pages10
JournalAnti-Cancer Drugs
Publication statusPublished - 1 Jan 2002


  • retinoids
  • differentiation therapy
  • apoptosis
  • prostate cancer


Dive into the research topics of 'The prospects of retinoids in the treatment of prostrate cancer'. Together they form a unique fingerprint.

Cite this